ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness

ClinicalTrials.gov ID: NCT03624920

Public ClinicalTrials.gov record NCT03624920. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 7:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Study identification

NCT ID
NCT03624920
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Theranexus
Industry
Enrollment
77 participants

Conditions and interventions

Interventions

  • THN102 Dosage A Drug
  • THN102 Dosage B Drug
  • THN102 Dosage C Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 11, 2018
Primary completion
Dec 19, 2019
Completion
Feb 23, 2020
Last update posted
Nov 30, 2020

2018 – 2020

United States locations

U.S. sites
3
U.S. states
3
U.S. cities
3
Facility City State ZIP Site status
University of Kansas Medical Center Kansas City Kansas 66160
MGH Neurological Clinical Research Institute Boston Massachusetts 02114
Houston Methodist Hospital Houston Texas 77030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 31 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03624920, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 30, 2020 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03624920 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →